Live Energy Minerals Corp
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 9.7K
- Market Cap
- -
- Introduction
Garrett Motion, Inc. provides automobile technology. The firm engages in the design, manufacture, and sale of engineered turbocharger, electric motor technologies for original equipment manufacturers and distributors within the mobility and industrial space. It offers light vehicle gasoline, light vehicle diesel, and commercial vehicle turbochargers. The company was founded on March 14, 2018 and is headquartered in Rolle, Switzerland.
Clinical Trials
19
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)β’ Click on a phase to view related trials
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence
- Locations
- πΊπΈ
Urology Center of Alabama, Homewood, Alabama, United States
πΊπΈCoastal Clinical Research Inc, Mobile, Alabama, United States
πΊπΈAlaska Clinical Research Center, Anchorage, Alaska, United States
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence
- Conditions
- Stress Urinary Incontinence
- Interventions
- Drug: Matching Placebo
- Locations
- πΊπΈ
Urology Center of Alabama, Homewood, Alabama, United States
πΊπΈCoastal Clinical Research Inc, Mobile, Alabama, United States
πΊπΈAlaska Clinical Research Center, Anchorage, Alaska, United States
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- GTx
- Target Recruit Count
- 491
- Registration Number
- NCT03241342
- Locations
- πΊπΈ
Urology Center of Alabama, Homewood, Alabama, United States
πΊπΈCoastal Clinical Research Inc, Mobile, Alabama, United States
πΊπΈAlaska Clinical Research Center, Anchorage, Alaska, United States
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
- Conditions
- ER+ and AR+ Breast Cancer
- Interventions
- Drug: GTx-024 9 or 18 mg
- Locations
- πΊπΈ
University of Washington, School of Medicine, Seattle, Washington, United States
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- GTx
- Target Recruit Count
- 19
- Registration Number
- NCT02658448
- Locations
- πΊπΈ
William Beaumont Hospital, Royal Oak, Michigan, United States
πΊπΈUrologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States
πΊπΈPenn Center for Continence and Pelvic Health, University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- Next